- 期刊
Local Intracoronary Infusion of Glycoprotein IIb/IIIa Inhibitors via a Perfusion Catheter versus Intracoronary Guiding Catheter Injection during Primary Percutaneous Coronary Intervention: A Pilot Observational Study
摘要
Background: Glycoprotein IIb IIIa inhibitors improved short- and long-term outcome when added to primary percutaneous coronary intervention (PPCI) in patients with ST-segment-elevation myocardial infarction (STEMI). We hypothesized that intracoronary eptifibatide infusion via a perfusion catheter improves angiographic and clinical outcome of patients with STEMI undergoing PPCI, versus conventional intracoronary bolus injection. Methods: Prospectively, we enrolled 80 patientswith acute STEMI and thrombolysis inmyocardial infarction (TIMI) thrombus grade ≧2. Patients were assigned to receive eptifibatide (180 μg) either via a dedicated coronary perfusion catheter (ClearWay^™) during PPCI (group I), or guiding catheter (group II). Assessment of TIMI thrombus grade, TIMI flow grade, and TIMI myocardial perfusion (TMP) grade was performed both at baseline and postprocedurally. The primary ‘angiographic’ endpoint was final TMP grade 0/1. The primary ‘clinical’ endpoint was a composite of cardiac death, non-fatal re-infarction, target vessel revascularization, and recurrent ischemia at 30-day follow-up. Results: Mean age was 52.3 ± 8.9 years (17.5% females). Clearance of visible thrombus (TIMI thrombus grade 0) at final angiogram was more frequent in group I. Additionally, both final TIMI flow grade 3 and final TMP grade 3 occurred more frequently in group I. The primary angiographic endpoint was more frequent in group II versus group I (17.5% versus 0%, respectively, p = 0.001). The primary clinical endpoint was more frequent in group II (20% versus 0%, respectively, p = 0.003). Conclusions: In patients with STEMI, intracoronary eptifibatide infusion via a perfusion catheter during PPCI improved immediate angiographic outcome, and reduced clinical events at 30-day follow-up, versus bolus injection via the guiding catheter.
延伸閱讀
- 王貞予（2014）。Concomitant use of Calcium Channel Blockers with Dual Antiplatelet Therapy and Recurrent Cardiovascular Events for Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2014.10648
- Li, Y. B., Li, Q., Li, F. O., Zong, M., Miao, G. B., Yang, X. C., Tong, Z. C., & Zhang, J. J. (2016). Evaluation of Short- and Long-Term Efficacy of Combined Intracoronary Administration of High-Dose Adenosine and Tirofiban during Primary Percutaneous Coronary Intervention. Acta Cardiologica Sinica, 32(6), 640-648. https://doi.org/10.6515/ACS20151013I
- 林小玲、楊麗瓊、梁巧儒、黃秀英、闕靜儀、明金蓮（2022）。Comparison of the Incidence of Peripheral Venous Catheter-Related Phlebitis Between 72- and 96- Hour Insertion in Medical Inpatients: A Cohort Observational Study。榮總護理，39(2)，172-186。https://doi.org/10.6142/VGHN.202206_39(2).0006
- Hajsadeghi, S., Chitsazan, M., Chitsazan, M., Salehi, N., Amin, A., Bidokhti, A. A., Babaali, N., Bordbar, A., Hejrati, M., & Moghadami, S. (2016). Prasugrel Results in Higher Decrease in High-Sensitivity C-Reactive Protein Level in Patients Undergoing Percutaneous Coronary Intervention Comparing to Clopidogrel. Clinical Medicine Insights: Cardiology, 2016(), 149-155. https://doi.org/10.4137/CMC.S32804
- Sung, L. C., Chen, Y. C., & Chang, B. S. (2009). Emergent Percutaneous Coronary Intervention under Extracorporeal Membrane Oxygenation Support for a Patient with Inferior St Elevation Myocardial Infarction and Refractory Shock: A Case Report and Lit. 重症醫學雜誌, 10(3), 248-255. https://www.airitilibrary.com/Article/Detail?DocID=1563356x-200909-10-3-248-255-a